117 related articles for article (PubMed ID: 38141473)
1. Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer.
Tiruye T; Roder D; FitzGerald LM; O'Callaghan M; Moretti K; Beckmann K
Cancer Epidemiol; 2024 Feb; 88():102516. PubMed ID: 38141473
[TBL] [Abstract][Full Text] [Related]
2. Does a Prescription-based Comorbidity Index Correlate with the American Society of Anesthesiologists Physical Status Score and Mortality After Joint Arthroplasty? A Registry Study.
Kerr MM; Graves SE; Duszynski KM; Inacio MC; de Steiger RN; Harris IA; Ackerman IN; Jorm LR; Lorimer MF; Gulyani A; Pratt NL
Clin Orthop Relat Res; 2021 Oct; 479(10):2181-2190. PubMed ID: 34232146
[TBL] [Abstract][Full Text] [Related]
3. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
Fallara G; Gedeborg R; Bill-Axelson A; Garmo H; Stattin P
PLoS One; 2021; 16(7):e0255239. PubMed ID: 34320037
[TBL] [Abstract][Full Text] [Related]
4. Impact of comorbidities on prostate cancer-specific mortality: A population-based cohort study.
Tiruye T; Roder D; FitzGerald LM; O'Callaghan M; Moretti K; Caughey GE; Beckmann K
Prostate; 2024 May; ():. PubMed ID: 38798040
[TBL] [Abstract][Full Text] [Related]
5. Validity of medication-based co-morbidity indices in the Australian elderly population.
Vitry A; Wong SA; Roughead EE; Ramsay E; Barratt J
Aust N Z J Public Health; 2009 Apr; 33(2):126-30. PubMed ID: 19413854
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the measurement of comorbidity for a South Australian colorectal cancer population using administrative data.
Pule L; Buckley E; Niyonsenga T; Roder D
J Eval Clin Pract; 2020 Aug; 26(4):1250-1258. PubMed ID: 31721394
[TBL] [Abstract][Full Text] [Related]
7. Developing a comorbidity index for comparing cancer outcomes in Aboriginal and non-Aboriginal Australians.
Pule L; Buckley E; Niyonsenga T; Banham D; Roder D
BMC Health Serv Res; 2018 Oct; 18(1):776. PubMed ID: 30326898
[TBL] [Abstract][Full Text] [Related]
8. The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System.
Pratt NL; Kerr M; Barratt JD; Kemp-Casey A; Kalisch Ellett LM; Ramsay E; Roughead EE
BMJ Open; 2018 Apr; 8(4):e021122. PubMed ID: 29654048
[TBL] [Abstract][Full Text] [Related]
9. Performance of comorbidity measures for predicting outcomes in population-based osteoporosis cohorts.
Lix LM; Quail J; Teare G; Acan B
Osteoporos Int; 2011 Oct; 22(10):2633-43. PubMed ID: 21305268
[TBL] [Abstract][Full Text] [Related]
10. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
11. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data.
Schneeweiss S; Wang PS; Avorn J; Maclure M; Levin R; Glynn RJ
J Gen Intern Med; 2004 May; 19(5 Pt 1):444-50. PubMed ID: 15109342
[TBL] [Abstract][Full Text] [Related]
12. Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions.
Iommi M; Rosa S; Fusaroli M; Rucci P; Fantini MP; Poluzzi E
PLoS One; 2020; 15(10):e0240899. PubMed ID: 33064757
[TBL] [Abstract][Full Text] [Related]
13. How valid is a prescription-based multimorbidity index (Rx-risk) in predicting mortality in the Outcomes and Multimorbidity In Type 2 diabetes (OMIT) study? A nation-wide registry-based cohort study from Norway.
Igland J; Forster R; Jenum AK; Strandberg RB; Berg TJ; Røssberg JI; Iversen MM; Buhl ES
BMJ Open; 2024 Mar; 14(3):e077027. PubMed ID: 38548358
[TBL] [Abstract][Full Text] [Related]
14. Any infection among patients with hip fracture: Predictive ability of Charlson, Elixhauser, Rx-Risk, and Nordic comorbidity indices.
Storbjerg DK; Gadgaard NR; Pedersen AB
Surgeon; 2024 Feb; 22(1):e61-e68. PubMed ID: 37989653
[TBL] [Abstract][Full Text] [Related]
15. A systematic review identifies valid comorbidity indices derived from administrative health data.
Yurkovich M; Avina-Zubieta JA; Thomas J; Gorenchtein M; Lacaille D
J Clin Epidemiol; 2015 Jan; 68(1):3-14. PubMed ID: 25441702
[TBL] [Abstract][Full Text] [Related]
16. Comparative Performance of Comorbidity Measures in Predicting Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease.
Zhan ZW; Chen YA; Dong YH
Int J Chron Obstruct Pulmon Dis; 2020; 15():335-344. PubMed ID: 32103932
[TBL] [Abstract][Full Text] [Related]
17. Improved comorbidity adjustment for predicting mortality in Medicare populations.
Schneeweiss S; Wang PS; Avorn J; Glynn RJ
Health Serv Res; 2003 Aug; 38(4):1103-20. PubMed ID: 12968819
[TBL] [Abstract][Full Text] [Related]
18. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent.
Boulos DL; Groome PA; Brundage MD; Siemens DR; Mackillop WJ; Heaton JP; Schulze KM; Rohland SL
Cancer; 2006 Apr; 106(8):1804-14. PubMed ID: 16534794
[TBL] [Abstract][Full Text] [Related]
19. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
[TBL] [Abstract][Full Text] [Related]
20. Predicting 7-year mortality for use with evidence-based guidelines for Prostate-Specific Antigen (PSA) testing: findings from a large prospective study of 123 697 Australian men.
Joshy G; Banks E; Lowe A; Wolfe R; Tickle L; Armstrong B; Clements M
BMJ Open; 2018 Dec; 8(12):e022613. PubMed ID: 30552254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
